The Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, recently reported its impact factor has once again increased, going from 20.4 for 2022 to 21.0 for 2023. The journal, which is led by Editor-in-Chief Alex A. Adjei, MD, PhD, has risen in rank to second among 100 respiratory medicine journals and remained steady at 13th among 322 oncology journals.
Impact factors are measured by calculating the number of times a journal’s articles from the two preceding years are cited in a current year. Thus, the impact factor for 2023 reflects the number of times articles published in 2021 and 2022 were cited in 2023. Journal citation reports are issued by Clarivate Analytics.
Since introducing the option to submit manuscripts with graphical abstracts last year, the JTO has published more than a dozen since mid-2023. Graphical abstracts provide an easy-to-follow visual summary of key contents and findings. When paired with a highly scientific article, the visual aid can enhance the reader’s experience and understanding of the contents in the article. A graphical abstract is also perfect to share on social media. The option to include a graphical abstract is available to Original Articles and Brief Reports only. Please visit JTO’s Guide for Author’s page for more details and/or instructions.
At the beginning of the year, the JTO officially became an online-only publication, with hybrid options to publish via subscription or open access. Visit JTO.org to browse various collections including the ongoing Lung Cancer Worldwide series, the monthly Editor’s Choice selections, and the IASLC’s proposals for the 9th Edition of the TNM Classification of Malignant Tumors.
14:00 PDT, Monday, September 9
Room 26B
Meet the Editor
Hear from the Editors-in-Chief of the Journal of Thoracic Oncology and JTO Clinical and Research Reports Alex A. Adjei, MD, PhD, and Emily Stone, MBBS, PhD, as they discuss the IASLC’s flagship journal and its open access companion.
As an open-access companion to JTO, the IASLC also publishes JTO Clinical and Research Reports (JTO CRR). JTO CRR, which is led by Editor-in-Chief Emily Stone, MBBS, PhD, recently received its first impact factor of 3.0. JTO CRR started publishing in 2020 and has grown steadily since. With its impact factor of 3.0, the journal ranks 37th among 100 respiratory journals and 142nd out of 322 oncology journals.
JTO CRR is also a 100% online journal, never having printed an issue. It is the official open access journal of the IASLC, providing free, non-subscription-based access to cutting edge research in the field worldwide. JTO CRR is now indexed on PubMed and WebofScience.
Learn more about the journals and hear from Drs. Adjei and Stone at a Meet-the-Editor session, which will take place at 14:00 PDT on Monday, September 9, in Room 26B. Attendees will have the chance to ask questions of the editors and hear from them as they discuss the journals and their individual experiences as editors-in-chief.
IASLC members receive a complimentary JTO subscription with their membership. Members also receive a 15% discount on JTO CRR publishing fees. Stop by the IASLC booth to check on your membership status or join today.
Both JTO and JTO CRR credit their editorial staffs for their continued success. Vun-Sin Lim, PhD, is the Managing Editor of JTO, and Becky Lindeman is the Managing Editor of JTO CRR. Adam Etkin serves as the Strategic Editorial Director of JTO CRR, and Bailey Creamer is the Editorial Assistant for both journals and the on-site journals’ staff liaison for the IASLC in Denver.
